Pfizer, Inc. (NYSE:PFE)‘s stock had its “buy” rating reiterated by investment analysts at BMO Capital Markets in a report issued on Thursday. They currently have a $37.00 target price on the biopharmaceutical company’s stock. BMO Capital Markets’ price target would suggest a potential upside of 5.53% from the company’s previous close.
Other research analysts have also issued reports about the stock. Jefferies Group LLC set a $35.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. Vetr lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price for the company. in a research note on Wednesday. Berenberg Bank set a $39.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, August 1st. Morgan Stanley reissued a “neutral” rating and set a $35.00 target price (down from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Finally, Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Friday, July 14th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the stock. Pfizer currently has a consensus rating of “Hold” and a consensus price target of $37.72.
Shares of Pfizer (NYSE:PFE) opened at 35.06 on Thursday. The firm has a market cap of $208.51 billion, a P/E ratio of 25.65 and a beta of 1.00. The company has a 50-day moving average of $33.44 and a 200-day moving average of $33.49. Pfizer has a 12 month low of $29.83 and a 12 month high of $35.75.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. Pfizer’s revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.64 EPS. Equities analysts forecast that Pfizer will post $2.56 EPS for the current fiscal year.
In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the transaction, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Laurie J. Olson sold 8,064 shares of the firm’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the transaction, the insider now owns 74,506 shares of the company’s stock, valued at approximately $2,436,346.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 426,291 shares of company stock valued at $14,475,911. 0.06% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. W. E. Donoghue & Co. LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at about $16,402,000. Intl Fcstone Inc. boosted its position in shares of Pfizer by 444.3% during the 2nd quarter. Intl Fcstone Inc. now owns 56,081 shares of the biopharmaceutical company’s stock valued at $1,884,000 after acquiring an additional 45,777 shares during the last quarter. M Holdings Securities Inc. boosted its position in shares of Pfizer by 41.5% during the 2nd quarter. M Holdings Securities Inc. now owns 26,036 shares of the biopharmaceutical company’s stock valued at $875,000 after acquiring an additional 7,635 shares during the last quarter. Griffin Asset Management Inc. bought a new stake in shares of Pfizer during the 2nd quarter valued at about $768,000. Finally, Farmers National Bank boosted its position in shares of Pfizer by 3.2% during the 2nd quarter. Farmers National Bank now owns 107,106 shares of the biopharmaceutical company’s stock valued at $3,598,000 after acquiring an additional 3,352 shares during the last quarter. Hedge funds and other institutional investors own 69.09% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.